Your browser is no longer supported. Please, upgrade your browser.
Settings
PCVX Vaxcyte, Inc. daily Stock Chart
PCVX [NASD]
Vaxcyte, Inc.
Index- P/E- EPS (ttm)-0.19 Insider Own2.20% Shs Outstand50.92M Perf Week27.58%
Market Cap2.41B Forward P/E- EPS next Y-2.52 Insider Trans0.00% Shs Float28.17M Perf Month-0.43%
Income-73.40M PEG- EPS next Q-0.44 Inst Own82.50% Short Float0.22% Perf Quarter42.37%
Sales- P/S- EPS this Y-70.50% Inst Trans- Short Ratio0.41 Perf Half Y-
Book/sh32.46 P/B1.55 EPS next Y59.90% ROA- Target Price49.50 Perf Year-
Cash/sh8.58 P/C5.88 EPS next 5Y-0.60% ROE- 52W Range17.80 - 55.04 Perf YTD93.00%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-8.30% Beta-
Dividend %- Quick Ratio12.60 Sales past 5Y- Gross Margin- 52W Low183.54% ATR4.59
Employees43 Current Ratio12.60 Sales Q/Q- Oper. Margin- RSI (14)65.96 Volatility11.42% 10.37%
OptionableNo Debt/Eq0.00 EPS Q/Q-488.80% Profit Margin- Rel Volume21.57 Prev Close49.42
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume152.70K Price50.47
Recom1.50 SMA2013.95% SMA5030.63% SMA20037.40% Volume3,294,148 Change2.12%
Jul-07-20Initiated Needham Buy $40
Jul-07-20Initiated Cantor Fitzgerald Overweight $55
Jul-07-20Initiated BofA Securities Buy $37
Sep-14-20 02:27PM  
Sep-09-20 05:28PM  
Aug-14-20 03:01PM  
Aug-12-20 04:59PM  
04:10PM  
Jun-16-20 04:05PM  
Jun-12-20 11:24AM  
06:18AM  
01:06AM  
Jun-03-20 08:30AM  
May-21-20 08:30AM  
Vaxcyte, Inc., a preclinical-stage biotechnology vaccine company, develops vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains causing significant invasive pneumococcal disease and antibiotic resistance; VAX-A1, a conjugate vaccine candidate for protection against subtypes of Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was founded in 2013 and is headquartered in Foster City, California.